Widened acceptance range w. a 2,2,2-study? [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2011-10-10 14:01 (5377 d 12:35 ago) – Posting: # 7457
Views: 5,099

Dear both
the procedure was finalized one year ago, October 6th 2010. Although at that time the new BE guideline was finalized it is very unlikely that this NfG was taken into considerations. I guess the study was conducted in 2009 according to the old guideline and the Q&A 2006 document. In contrast to immediate release oral formulations the applicant performed three studies for a modifies release formulation and based on the results of all three studies the assessor judged the product to be bioequivalent to the reference even if the tighter acceptance range in one study was not met. Fed studies are known to have a higher variability. I assume the applicant agreed with this decision. However, it will be hard for a competitor to claim the same.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
340 visitors (0 registered, 340 guests [including 44 identified bots]).
Forum time: 02:36 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5